Shujaat Adil, Bajwa Abubakr A, Cury James D
Division of Pulmonary, Critical Care & Sleep Medicine, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA.
Pulm Med. 2012;2012:203952. doi: 10.1155/2012/203952. Epub 2012 Aug 29.
The development of pulmonary hypertension in COPD adversely affects survival and exercise capacity and is associated with an increased risk of severe acute exacerbations. Unfortunately not all patients with COPD who meet criteria for long term oxygen therapy benefit from it. Even in those who benefit from long term oxygen therapy, such therapy may reverse the elevated pulmonary artery pressure but cannot normalize it. Moreover, the recent discovery of the key roles of endothelial dysfunction and inflammation in the pathogenesis of PH provides the rationale for considering specific pulmonary vasodilators that also possess antiproliferative properties and statins.
慢性阻塞性肺疾病(COPD)中肺动脉高压的发展会对生存率和运动能力产生不利影响,并与严重急性加重风险增加相关。不幸的是,并非所有符合长期氧疗标准的COPD患者都能从中获益。即使在那些从长期氧疗中获益的患者中,这种治疗可能会降低升高的肺动脉压力,但无法使其恢复正常。此外,最近发现内皮功能障碍和炎症在肺动脉高压发病机制中的关键作用,为考虑使用具有抗增殖特性的特定肺血管扩张剂和他汀类药物提供了理论依据。